These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23160303)

  • 1. The entire predictive value of the prometheus IBD sgi diagnostic product may be due to the three least expensive and most available components.
    Shirts B; von Roon AC; Tebo AE
    Am J Gastroenterol; 2012 Nov; 107(11):1760-1. PubMed ID: 23160303
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia.
    Sabery N; Bass D
    Pediatrics; 2007 Jan; 119(1):e193-9. PubMed ID: 17158948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IBD SGI Diagnostic Test Is Frequently Used by Non-gastroenterologists to Screen for Inflammatory Bowel Disease.
    Berinstein JA; Waljee AK; Stidham RW; Higgins PDR; Govani SM
    Inflamm Bowel Dis; 2018 Apr; 24(5):e18. PubMed ID: 29688480
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical evaluation of serologic markers for inflammatory bowel disease.
    Austin GL; Herfarth HH; Sandler RS
    Clin Gastroenterol Hepatol; 2007 May; 5(5):545-7. PubMed ID: 17433787
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnostic value of serological assays in pediatric inflammatory bowel disorders.
    Mainardi E; Villanacci V; Bassotti G; Liserre B; Rossi E; Incardona P; Falchetti D; Tonegatti L; Montanelli A; Barabino A; Coccia C; Gambini C
    Digestion; 2007; 75(4):210-4. PubMed ID: 17952008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?
    Sidhu R; Wilson P; Wright A; Yau CW; D'Cruz FA; Foye L; Morley S; Lobo AJ; McAlindon ME; Sanders DS
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1365-70. PubMed ID: 20331581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calprotectin: a fecal marker for diagnosis and follow-up in patients with chronic inflammatory bowel disease].
    van den Bergh FA; Kolkman JJ; Russel MG; Vlaskamp RT; Vermes I
    Ned Tijdschr Geneeskd; 2003 Nov; 147(48):2360-5. PubMed ID: 14677476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.
    von Roon AC; Karamountzos L; Purkayastha S; Reese GE; Darzi AW; Teare JP; Paraskeva P; Tekkis PP
    Am J Gastroenterol; 2007 Apr; 102(4):803-13. PubMed ID: 17324124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategies.
    Dubinsky MC; Johanson JF; Seidman EG; Ofman JJ
    Am J Gastroenterol; 2002 Sep; 97(9):2333-42. PubMed ID: 12358253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic antiglycan antibodies in inflammatory bowel disease.
    Lakatos PL; Papp M; Rieder F
    Am J Gastroenterol; 2011 Mar; 106(3):406-12. PubMed ID: 21245832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of autoantibodies in inflammatory bowel disease.
    Herszényi L; Tulassay Z
    Dig Dis; 2012; 30(2):201-7. PubMed ID: 22722439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS; Chapman RW; Fleming KA
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shortcomings of the inflammatory bowel disease Serology 7 panel.
    Benor S; Russell GH; Silver M; Israel EJ; Yuan Q; Winter HS
    Pediatrics; 2010 Jun; 125(6):1230-6. PubMed ID: 20439597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of fecal markers of inflammation in inflammatory bowel disease.
    Judd TA; Day AS; Lemberg DA; Turner D; Leach ST
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1493-9. PubMed ID: 21777275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers that differentiate early from late IBD.
    Huang C; Kugathasan S
    Dig Dis; 2012; 30(4):380-2. PubMed ID: 22796800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease.
    Dubinsky MC; Ofman JJ; Urman M; Targan SR; Seidman EG
    Am J Gastroenterol; 2001 Mar; 96(3):758-65. PubMed ID: 11280547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological markers in inflammatory bowel disease: practical consideration for clinicians.
    Mendoza JL; Abreu MT
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S158-73. PubMed ID: 20117339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
    Arai R
    Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic biomarkers in inflammatory bowel disease].
    Kanmura S; Sakiyama T; Uto H; Tsubouchi H
    Nihon Rinsho; 2012 May; 70(5):790-5. PubMed ID: 22620002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation.
    Buckland MS; Mylonaki M; Rampton D; Longhurst HJ
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1328-30. PubMed ID: 16275949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.